Bausch Health resolves IP litigation with Teva
02-08-2019
Bausch Health settles generic dispute with Actavis
13-09-2018
Pavel Kapysh / Shutterstock.com
Canadian pharmaceutical company Bausch Health and India-based Glenmark Pharmaceuticals have resolved their outstanding IP litigation over Bryhali (halobetasol propionate) lotion.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Bausch Health, Glenmark Pharmaceuticals, Ortho Dermatologics, psoriasis, settlement, patent infringement, ANDA, generics, FDA
